Hepatic veno-occlusive disease after tranexamic acid administration in oatients undergoing allogeneic hematopoietic stem cell transplantation

American Journal of Hematology

Volumn 82, Issue 9, 2007, Pages 838-839

  Mori, Takehiko ^a   Aisa, Yoshinobu ^a   Shimizu, Takayuki ^a   Yamazaki, Rie ^a   Mihara, Ai ^a   Yajima, Tomoharu ^a   Hibi, Toshifumi ^a   Ikeda, Yasuo ^a   Okamoto, Shinichiro ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANTIFIBRINOLYTIC AGENT; BILIRUBIN; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; MELPHALAN; METHOTREXATE; PLASMINOGEN; TACROLIMUS; TRANEXAMIC ACID; RECOMBINANT PROTEIN; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLEEDING; CASE REPORT; DRUG WITHDRAWAL; FEMALE; FLUID RETENTION; HEPATOMEGALY; HUMAN; LIVER VENOOCCLUSIVE DISEASE; MALE; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; PRIORITY JOURNAL; RARE DISEASE; SCHOOL CHILD; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; BLOOD; CHEMICALLY INDUCED DISORDER; CHILD; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LIVER VEIN OBSTRUCTION; MIDDLE AGED; PATHOPHYSIOLOGY; RISK FACTOR; TREATMENT OUTCOME;

ANTIFIBRINOLYTIC AGENTS; BILIRUBIN; CHILD; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RISK FACTORS; THROMBOCYTOPENIA; TISSUE PLASMINOGEN ACTIVATOR; TRANEXAMIC ACID; TREATMENT OUTCOME;

EID: 35748958758     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20958     Document Type: Article

References (18)

1. McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation. Ann Intern Med 1993;118:255-267.
2. Carreras E. Veno-occlusive disease of the liver after hemopoietic cell transplantation. Eur J Haematol 2000;64:281-291.
3. Valteau-Couanet D, Benhamou E. Vassal G, et al. Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma. Bone Marrow Transplant 2000;25:937-942.
4. Vassal G, Kosciently S, Challine D, et al. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation. Cancer Chemother Phamacol 1996;37:247-253.
5. Meresse V, Hartmann O, Vassal G, et al. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: A study in 136 children. Bone Marrow Transplant 1992;10:135-141.
6. Essel JH, Thompson JM, Harman GS, et al. Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/ cyclophosphamide. Blood 1992;79:2784-2788.
7. Arceci RJ, Sande J, Lange B, et al. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute leukemia. Blood 2005;106:1183-1188.
8. Mannucci PM. Hemostatic drugs. New Engl J Med 1998;339:245.
9. Dunn CJ, Goa K. Tranexamic acid: A review of its use in surgery and other indications. Drugs 1999;57:1005-1032.
10. Porte RJ, Leebeek FWG. Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery. Drugs 2002;62:2193-2211.
11. Dalmau A, Sabate A, Acosta P, et al. Tranexamic acid reduces red cell transfusion better than ε-aminocaproic acid or placebo in liver transplantation. Anesth Analg 2000;91:29-34.
12. Berntorp E, Follrud C, Lethagen S. No increased risk of venous thrombosis in women taking tranexamic acid. Thromb Haemost 2000;86:714-715.
13. Dalmau A, Sabate A, Koo M, Rafecas A, Figueras J. Jaurrieta E. Prophylactic use of tranexamic acid and incidence of arterial thrombosis in liver transplantation. Anesth Analg 2001;93:516.
14. Woo KS, Tse LKK, Woo JLF, Vallance-Owen J. Massive pulmonary throboembolism after tranexamic acid fibrinolytic therapy. Br J Clin Pract 1989;43:465-466.
15. Taparia M, Cordingley FT, Leahy MF. Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia. Eur J Haematol 2002;68:307-309.
16. Salat C, Holler E, Kolb HJ, et al. The relevance of plasminogen activator inhibitor 1 (PAI-1) as a marker for the diagnosis of hepatic veno-occlusive disease in patients after bone marrow transplantation. Leuk Lymphoma 1999;33:25-32.
17. Salat C, Holler E, Kolb HJ, et al. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. Blood 1997;89:2184-2188.
18. Smith LH, Dixon JD, Stringham JR, et al. Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis. Blood 2006;107:132-134.